RxDoctor Payments Data

Shawn Murdock, MD

Family Medicine · North Platte, NENPI 1508989427

Payments from drug & device makers

$1,976in general payments, 2019–2025

Across 127 payments — averaging $15.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$250
  • Amgen$235
  • Pfizer$203
  • AbbVie$192
  • Daiichi Sankyo Inc.$170
  • Johnson & Johnson$130
  • plus $795 from 22 others

What the payments were for

  • Food & beverage$1,976100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,976 in reported general payments places this provider in the 70th percentile of 981 family medicine providers in Nebraska.

See all family medicine providers in Nebraska

Medicare billing

Part B allowed, 2024
$386,092
Medicare patients
765
Services billed
12,216

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban423$286,999
JardianceEmpagliflozin317$202,929
XareltoRivaroxaban203$148,544
JanuviaSitagliptin Phosphate116$81,361
MyrbetriqMirabegron105$60,405
TrulicityDulaglutide41$51,235
Trelegy ElliptaFluticasone/Umeclidin/Vilanter67$44,664
OzempicSemaglutide46$41,084
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog48$32,787
EntrestoSacubitril/Valsartan44$27,318
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog47$22,039
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr46$20,957
WegovySemaglutide13$19,132
Lantus SolostarInsulin Glargine,hum.Rec.Anlog152$17,680
LinzessLinaclotide32$16,819

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$203$286,999423 claims
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$81$224,639351 claims
Johnson & JohnsonXarelto$130$148,544203 claims
MerckJanuvia, Janumet$11$91,792134 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta$52$86,714169 claims
Novo NordiskOzempic, Wegovy$250$60,21659 claims
Lilly USA, LLCTrulicity$119$51,23541 claims
NovartisEntresto$20$27,31844 claims
AstraZenecaBreztri Aerosphere, Farxiga$24$20,66537 claims
AbbVieLinzess$192$16,81932 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 981 family medicine providers in Nebraska.

Other family medicine in North Platte

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →